- Home
- GF vs VTYX Comparison
GF vs VTYX Comparison
Compare GF & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- VTYX
- Stock Information
- Founded
- GF 1990
- VTYX 2018
- Country
- GF Germany
- VTYX United States
- Employees
- GF N/A
- VTYX N/A
- Industry
- GF Investment Managers
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- GF Finance
- VTYX Health Care
- Exchange
- GF Nasdaq
- VTYX Nasdaq
- Market Cap
- GF 183.3M
- VTYX 154.9M
- IPO Year
- GF N/A
- VTYX 2021
- Fundamental
- Price
- GF $11.33
- VTYX $6.55
- Analyst Decision
- GF
- VTYX Buy
- Analyst Count
- GF 0
- VTYX 3
- Target Price
- GF N/A
- VTYX $10.00
- AVG Volume (30 Days)
- GF 28.1K
- VTYX 9.0M
- Earning Date
- GF 01-01-0001
- VTYX 11-06-2025
- Dividend Yield
- GF 0.82%
- VTYX N/A
- EPS Growth
- GF N/A
- VTYX N/A
- EPS
- GF N/A
- VTYX N/A
- Revenue
- GF N/A
- VTYX N/A
- Revenue This Year
- GF N/A
- VTYX N/A
- Revenue Next Year
- GF N/A
- VTYX N/A
- P/E Ratio
- GF N/A
- VTYX N/A
- Revenue Growth
- GF N/A
- VTYX N/A
- 52 Week Low
- GF $7.38
- VTYX $0.78
- 52 Week High
- GF $9.41
- VTYX $7.82
- Technical
- Relative Strength Index (RSI)
- GF 44.79
- VTYX 75.26
- Support Level
- GF $11.06
- VTYX $5.75
- Resistance Level
- GF $11.24
- VTYX $7.82
- Average True Range (ATR)
- GF 0.16
- VTYX 0.47
- MACD
- GF -0.03
- VTYX 0.27
- Stochastic Oscillator
- GF 35.59
- VTYX 72.11
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.